Improving Alzheimer’s disease imaging — with fluorescent sensors

Neurotransmitter levels in the brain can indicate brain health and neurodegenerative diseases like Alzheimer’s. However, the protective blood-brain barrier (BBB) makes delivering fluorescent sensors that can detect these small molecules to the brain difficult. Now, researchers in ACS Central Science demonstrate a way of packaging these sensors for easy passage across the BBB in mice, allowing for improved brain imaging. With further development, the technology could help advance Alzheimer’s disease diagnosis and treatment.

It is common for neurotransmitter levels to decrease with age, but low levels of the neurotransmitter adenosine triphosphate (ATP) can be an indication of Alzheimer’s disease. To measure the location and amount of ATP in the brain, researchers have developed fluorescent sensors from pieces of DNA called aptamers that light up when they bind to a target molecule. Methods for delivering these sensors from the bloodstream to the brain have been developed, but most contain synthetic components that can’t easily cross the BBB. To develop sensors for live brain imaging, Yi Lu and colleagues encapsulated an ATP aptamer sensor in brain-cell derived microscopic vesicles called exosomes. They tested the new sensor delivery system in lab models of the BBB and in mouse models of Alzheimer’s disease.   

The BBB laboratory model consisted of a layer of endothelial cells on top of a solution containing brain cells. The researchers’ sensor-loaded exosomes were nearly four times more efficient than conventional sensor delivery systems at passing through the endothelial barrier and releasing the fluorescent sensor into the brain cells. This was confirmed by measuring the observed level of ATP-binding-induced fluorescence. Next, Lu’s team injected mouse models of Alzheimer’s disease with either the sensor-loaded exosomes or free-floating unloaded sensors. By measuring fluorescence signals in the mice, the researchers found that the free-floating sensors stayed mainly in the blood, liver, kidneys and lungs, while sensors delivered via exosomes accumulated in the brain. 

In mouse models of Alzheimer’s disease, the exosome-delivered sensors identified the location and concentration of ATP in different regions of the brain. Specifically, they observed low levels of ATP in the hippocampus, cortex and subiculum regions of the brain, which are indicative of the disease. The researchers say that their exosome-loaded ATP-reactive sensors show promise for non-invasive live brain imaging and could be developed further to create sensors for a range of clinically relevant neurotransmitters.

The authors acknowledge funding from the U.S. National Institutes of Health (NIH), Welch Foundation, NIH Chemistry-Biology Interface Training Program at the University of Illinois Urbana-Champaign and a National Science Foundation Graduate Research Fellowship.

The paper’s abstract will be available on July 31 at 8 a.m. Eastern time here: http://pubs.acs.org/doi/10.1021/acscentsci.4c00563

For more of the latest research news, register for our upcoming meeting, ACS Fall 2024. Journalists and public information officers are encouraged to apply for complimentary press registration by completing this form.

###

The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS’ mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and all its people. The Society is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACS’ main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.

Note: ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies.

Follow us: X, formerly Twitter | Facebook | LinkedIn | Instagram